Year None202420232022202120202019 Jan 22, 2024 ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the Jan 14, 2024 Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% Accord Jan 14, 2024 ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Displaying 19 - 21 of 21